Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 25 (12), 1928-1937

High-intensity Sequencing Reveals the Sources of Plasma Circulating Cell-Free DNA Variants

Affiliations
Clinical Trial

High-intensity Sequencing Reveals the Sources of Plasma Circulating Cell-Free DNA Variants

Pedram Razavi et al. Nat Med.

Abstract

Accurate identification of tumor-derived somatic variants in plasma circulating cell-free DNA (cfDNA) requires understanding of the various biological compartments contributing to the cfDNA pool. We sought to define the technical feasibility of a high-intensity sequencing assay of cfDNA and matched white blood cell DNA covering a large genomic region (508 genes; 2 megabases; >60,000× raw depth) in a prospective study of 124 patients with metastatic cancer, with contemporaneous matched tumor tissue biopsies, and 47 controls without cancer. The assay displayed high sensitivity and specificity, allowing for de novo detection of tumor-derived mutations and inference of tumor mutational burden, microsatellite instability, mutational signatures and sources of somatic mutations identified in cfDNA. The vast majority of cfDNA mutations (81.6% in controls and 53.2% in patients with cancer) had features consistent with clonal hematopoiesis. This cfDNA sequencing approach revealed that clonal hematopoiesis constitutes a pervasive biological phenomenon, emphasizing the importance of matched cfDNA-white blood cell sequencing for accurate variant interpretation.

Comment in

Similar articles

See all similar articles

Cited by 5 articles

References

    1. Stroun M, Anker P, Lyautey J, Lederrey C & Maurice PA Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 23, 707–712 (1987). - PubMed
    1. Leon SA, Shapiro B, Sklaroff DM & Yaros MJ Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37, 646–650 (1977). - PubMed
    1. Jr LAD & Bardelli A Liquid Biopsies: Genotyping Circulating Tumor DNA. Journal of Clinical Oncology 32, 579–586 (2014). - PMC - PubMed
    1. Wan JCM, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 17, 223–238 (2017). - PubMed
    1. Lanman RB, et al. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLoS One 10, e0140712 (2015). - PMC - PubMed

Methods-Only References

    1. Tamborero D, Gonzalez-Perez A & Lopez-Bigas N OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes. Bioinformatics 29, 2238–2244 (2013). - PubMed
    1. Shen R & Seshan VE FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res 44, e131 (2016). - PMC - PubMed
    1. Carter SL, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 30, 413–421 (2012). - PMC - PubMed
    1. Ulmert D, et al. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol 62, 78–84 (2012). - PMC - PubMed
    1. Armstrong AJ, et al. Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 4, 944–951 (2018). - PMC - PubMed

Publication types

LinkOut - more resources

Feedback